BACKGROUND: Reported data regarding @entity6537 ( @entity6537 ) management are anecdotal. Cases of @entity6537 included in an international multicentre series of 378 immunocompetent @entity1 with @entity149 ( @entity149 ) were reviewed. @entity1 AND METHODS: Staging included slit-lamp examination in 170 @entity1 : @entity6537 was diagnosed in 22 cases (13%). A concomitant @entity75 was detected in 21 cases. Planned treatment was chemotherapy followed by radiotherapy in 13 cases, chemotherapy alone in three and radiotherapy, followed by or not by chemotherapy in five; one @entity1 was not treated. Chemotherapy included high-dose @entity1499 in 12 cases. Ten @entity1 received intrathecal chemotherapy. Radiotherapy consisted of whole brain irradiation, followed by or not by a @entity5 bed boost; ocular irradiation was planned in 15 cases. Irradiation in one @entity1 without @entity75 was limited to the orbits only (50 Gy). RESULTS: @entity6537 was positively correlated to @entity66 . Fifteen @entity1 (71%) achieved an objective response; 16 @entity1 experienced a failure (2-year failure-free survival 34+/-10%). @entity2194 in eight cases, with a 2-year time to ocular relapse of 59+/-11%. Ocular failure was less common in @entity1 treated with chemotherapy plus ocular irradiation and was associated with a significantly shorter survival. Seven @entity1 are alive [median follow-up 53 months, 2-year overall survival (OS): 39+/-11%] , five of whom were treated with ocular irradiation. The @entity1 with @entity6537 is alive and disease-free at 14 months. OS of the entire series was similar to that of PCNSL @entity1 with negative slit-lamp examination. CONCLUSIONS: @entity6537 is usually associated with concomitant @entity75 and shows a survival similar to that of the rest of @entity149 . Chemotherapy combined with ocular irradiation resulted in better control of @entity2194 , which seems to be associated with survival. In view of the potential role of ocular irradiation, the use of chemotherapy alone in phase II trials should be critically reconsidered in PCNSL @entity1 with @entity2194 .

Relevance of intraocular involvement in the management of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['Failures involved the eyes', 'ocular disease'] @entity66 :: ('MESH:D004194', 'Disease') :: ['systemic symptoms and meningeal disease'] @entity75 :: ('MESH:D001927', 'Disease') :: ['brain lesion', 'brain disease', 'brain lesions'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity149 :: ('MESH:D002493', 'Disease') :: ['primary central nervous system lymphomas', 'PCNSLs'] @entity6537 :: ('MESH:D064090', 'Disease') :: ['isolated IOL', 'intraocular lymphoma', 'IOL'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity149 :: (MESH:D002493,Disease) :: ['primary central nervous system lymphomas']
